The role of artesunate for the treatment of urinary schistosomiasis in schoolchildren: A systematic review and meta-analysis

Pathogens and Global Health

Volumn 106, Issue 7, 2012, Pages 397-404

  Wikman Jorgensen, Philip Erik ^a   Henríquez Camacho, César Augusto ^b   Serrano Villar, Sergio ^b   Pérez Molina, Jose Antonio ^c  

^a HOSPITAL UNIVERSITARIO DE SAN JUAN   (Spain)

^b HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^c HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

Artemisinin derivatives; Artesunate; Meta analysis; Praziquantel; Schistosomiasis

Indexed keywords

ARTESUNATE; MEFLOQUINE; PLACEBO; PRAZIQUANTEL; PYRIMETHAMINE; SULFALENE;

EMBASE; HUMAN; INFECTION; MEDLINE; META ANALYSIS; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK; SCHISTOSOMIASIS; SYSTEMATIC REVIEW; TROPICAL MEDICINE; UNSPECIFIED SIDE EFFECT; URINARY SCHISTOSOMIASIS;

ADOLESCENT; ANTHELMINTICS; ARTEMISININS; CHILD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; PRAZIQUANTEL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCHISTOSOMIASIS HAEMATOBIA; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84871280212     PISSN: 20477724     EISSN: 20477732     Source Type: Journal    
DOI: 10.1179/2047773212Y.0000000038     Document Type: Review

References (45)

1. Steinmann P, Keiser J, Bos R, Tanner M, Utzinger J. Schistosomiasis and water resources development: systematic review, meta-analysis, and estimates of people at risk. Lancet Infect Dis. 2006;6(7):411-25.
2. Ahmed AA, Afifi AA, Adam I. High prevalence of Schistosoma haematobium infection in Gereida Camp, in southern Darfur, Sudan. Ann Trop Med Parasitol. 2009;103(8):741-3.
3. Ekpo UF, Laja-Deile A, Oluwole AS, Sam-Wobo SO, Mafiana CF. Urinary schistosomiasis among preschool children in a rural community near Abeokuta, Nigeria. Parasit Vectors. 2010;3:58.
4. King CH, Dickman K, Tisch DJ. Reassessment of the cost of chronic helmintic infection: a meta-analysis of disability-related outcomes in endemic schistosomiasis. Lancet. 2005;365 (9470):1561-9.
5. King CH. Parasites and poverty: the case of schistosomiasis. Acta Trop. 2010;113(2):95-104.
6. Mostafa MH, Sheweita SA, O'Connor PJ. Relationship between schistosomiasis and bladder cancer. Clin Microbiol Rev. 1999;12(1):97-111.
7. Danso-Appiah A, Utzinger J, Liu J, Olliaro P. Drugs for treating urinary schistosomiasis. Cochrane Database Syst Rev. 2008;(3):CD000053
8. 2+ channels targets of praziquantel action? Int J Parasitol. 2005;35(1):1-9.
9. Doenhoff MJ, Cioli D, Utzinger J. Praziquantel: mechanisms of action, resistance and new derivatives for schistosomiasis. Curr Opin Infect Dis. 2008;21(6):659-67.
10. Gray DJ, Ross AG, Li YS, McManus DP. Diagnosis and management of schistosomiasis. BMJ. 2011;342:d2651.
11. Olliaro P., Vaillant MT, Belizario VJ, Lwambo NJ, Ouldabdallahi M, Pieri OS, et al. A multicentre randomized controlled trial of the efficacy and safety of single-dose praziquantel at 40 mg/kg vs. 60 mg/kg for treating intestinal schistosomiasis in the Philippines, Mauritania, Tanzania and Brazil. PLoS Negl Trop Dis. 2011;5(6):e1165.
12. Dietze R, Prata A. Rate of reversion of hepatosplenic schistosomiasis after specific therapy. Rev Soc Bras Med Trop. 1986;19(2):69-73.
13. Doehring-Schwerdtfeger E, Abdel-Rahim IM, Kardorff R, Kaiser C, Franke D, Schlake J, et al. Ultrasonographical investigation of periportal fibrosis in children with Schistosoma mansoni infection: reversibility of morbidity twenty-three months after treatment with praziquantel. Am J Trop Med Hyg. 1992;46(4):409-15.
14. Gryseels B. The relevance of schistosomiasis for public health. Trop Med Parasitol. 1989;40(2):134-42.
15. Richter J. Evolution of schistosomiasis-induced pathology after therapy and interruption of exposure to schistosomes: a review of ultrasonographic studies. Acta Trop. 2000;77(1):111-31.
16. Hatz CF, Vennervald BJ, Nkulila T, Vounatsou P, Kombe Y, Mayombana C, et al. Evolution of Schistosoma haematobiumrelated pathology over 24 months after treatment with praziquantel among school children in southeastern Tanzania. Am J Trop Med Hyg. 1998;59(5):775-81.
17. Olds GR. Administration of praziquantel to pregnant and lactating women. Acta Trop. 2003;86(2-3):185-95.
18. WHO. Prevention and control of schistosomiasis and soiltransmitted helminthiasis. World Health Organ Tech Rep Ser. 2002;912:1-6, 1-57, back cover.
19. Danso-Appiah A, de Vlas SJ. Interpreting low praziquantel cure rates of Schistosoma mansoni infections in Senegal. Trends Parasitol. 2002;18(3):125-9.
20. Alonso D, Munoz J, Gascon J, Valls ME, Corachan M. Failure of standard treatment with praziquantel in two returned travelers with Schistosoma haematobium infection. Am J Trop Med Hyg. 2006;74(2):342-4.
21. Ismail M, Botros S, Metwally A, William S, Farghally A, Tao LF, et al. Resistance to praziquantel: direct evidence from Schistosoma mansoni isolated from Egyptian villagers. Am J Trop Med Hyg. 1999;60(6):932-5.
22. Messerli SM, Kasinathan RS, Morgan W, Spranger S, Greenberg RM. Schistosoma mansoni P-glycoprotein levels increase in response to praziquantel exposure and correlate with reduced praziquantel susceptibility. Mol Biochem Parasitol. 2009;167(1):54-9.
23. Kasinathan RS, Goronga T, Messerli SM, Webb TR, Greenberg RM. Modulation of a Schistosoma mansoni multidrug transporter by the antischistosomal drug praziquantel. FASEB J. 2010;24(1):128-35.
24. WHO. Guidelines for the treatment of malaria. 2nd ed. Geneva: WHO; 2010.
25. Utzinger J, Xiao S, Keiser J, Chen M, Zheng J, Tanner M. Current progress in the development and use of artemether for chemoprophylaxis of major human schistosome parasites. Curr Med Chem. 2001;8(15):1841-60.
26. Adam I, Elhardello OA, Elhadi MO, Abdalla E, Elmardi KA, Jansen FH. The antischistosomal efficacies of artesunate-sulfamethoxypyrazine-pyrimethamine and artemether-lumefantrine administered as treatment for uncomplicated, Plasmodium falciparum malaria. Ann Trop Med Parasitol. 2008;102(1):39-44.
27. Boulanger D, Dieng Y, Cisse B, Remoue F, Capuano F, Dieme JL, et al. Antischistosomal efficacy of artesunate combination therapies administered as curative treatments for malaria attacks. Trans R Soc Trop Med Hyg. 2007;101(2):113-6.
28. Liu R, Dong HF, Guo Y, Zhao QP, Jiang MS. Efficacy of praziquantel and artemisinin derivatives for the treatment and prevention of human schistosomiasis: a systematic review and meta-analysis. Parasit Vectors. 2011;4:201.
29. Shuhua X, Jiqing Y, Jinying M, Huifang G, Peiying J, Tanner M. Effect of praziquantel together with artemether on Schistosoma japonicum parasites of different ages in rabbits. Parasitol Int. 2000;49(1):25-30.
30. Xiao S, Utzinger J, Chollet J, Endriss Y, N'Goran EK, Tanner M. Effect of artemether against Schistosoma haematobium in experimentally infected hamsters. Int J Parasitol. 2000; 30(9):1001-6.
31. Higgins JP, Altman D. Assessing risk of bias in included studies. In: Higgins J, Green S, editors. Cochrane handbook of systematic reviews of interventions. Chichester: John Wiley & Sons; 2008, 187-241.
32. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539-58.
33. Borrmann S, Szlezak N, Faucher JF, Matsiegui PB, Neubauer R, Binder RK, et al. Artesunate and praziquantel for the treatment of Schistosoma haematobium infections: a doubleblind, randomized, placebo-controlled study. J Infect Dis. 2001;184(10):1363-6.
34. de Clercq D, Vercruysse J, Kongs A, Verle P, Dompnier JP, Faye PC. Efficacy of artesunate and praziquantel in Schistosoma haematobium infected schoolchildren. Acta Trop. 2002;82(1):61-6.
35. Sissoko MS, Dabo A, Traore H, Diallo M, Traore B, Konate D, et al. Efficacy of artesunate + sulfamethoxypyrazine/ pyrimethamine versus praziquantel in the treatment of Schistosoma haematobium in children. PLoS ONE. 2009;4(10):e6732.
36. Inyang-Etoh PC, Ejezie GC, Useh MF, Inyang-Etoh EC. Efficacy of a combination of praziquantel and artesunate in the treatment of urinary schistosomiasis in Nigeria. Trans R Soc Trop Med Hyg. 2009;103(1):38-44.
37. Keiser J, N'Guessan NA, Adoubryn KD, Silue KD, Vounatsou P, Hatz C, et al. Efficacy and safety of mefloquine, artesunate, mefloquine-artesunate, and praziquantel against Schistosoma haematobium: randomized, exploratory open-label trial. Clin Infect Dis. 2010;50(9):1205-13.
38. Gryseels B, Polman K, Clerinx J, Kestens L. Human schistosomiasis. Lancet. 2006;368(9541):1106-18.
39. White N. Antimalarial drug resistance and combination chemotherapy. Philos Trans R Soc Lond B Biol Sci. 1999;354(1384):739-49.
40. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557-60.
41. Utzinger J, N'Goran EK, N'Dri A, Lengeler C, Xiao S, Tanner M. Oral artemether for prevention of Schistosoma mansoni infection: randomised controlled trial. Lancet. 2000;355 (9212):1320-5.
42. Li YS, Chen HG, He HB, Hou XY, Ellis M, McManus DP. A double-blind field trial on the effects of artemether on Schistosoma japonicum infection in a highly endemic focus in southern China. Acta Trop. 2005;96(2-3):184-90.
43. Zhang W, Wong CM. Evaluation of the 1992-1999 World Bank Schistosomiasis Control Project in China. Acta Trop. 2003;85(3):303-13.
44. Magnussen P. Treatment and re-treatment strategies for schistosomiasis control in different epidemiological settings: a review of 10 years' experiences. Acta Trop. 2003;86(2-3):243- 54.
45. Minai M, Hosaka Y, Ohta N. Historical view of schistosomiasis japonica in Japan: implementation and evaluation of disease-control strategies in Yamanashi Prefecture. Parasitol Int. 2003;52(4):321-6.